NEW YORK, April 3, 2015 /PRNewswire/ -- The fairness of the
proposed acquisition of Hyperion Therapeutics, Inc. ("HPTX" or the
"Company") by Horizon Pharma Plc ("Horizon") is being investigated
by WeissLaw LLP, a national class action, shareholder rights law
firm. The investigation focuses on possible breaches of
fiduciary duty and other violations of law by the Board of
Directors of HPTX for agreeing to sell the Company to
Horizon. On March 30, 2015, the
Company announced a definitive agreement for Horizon to acquire
HPTX in a transaction valued at approximately $1.1 billion. Under the terms of the
agreement, HPTX shareholders will receive $46.00 in cash for each HPTX share they
own.
WeissLaw is investigating whether HPTX's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, at least one analyst set a price target of $52.00 per share, or $6.00 above the offer price. Additionally,
the offer price represents a premium of less than 2% over the
Company March 27, 2015 trading price
of $45.40.
Given these facts, WeissLaw is investigating whether HPTX's
Board acted in the best interests of HPTX's public shareholders by
actively shopping the Company to maximize shareholder value prior
to entering into the agreement with Horizon. If you own HPTX
shares and would like more information about your rights or our
investigation, or if you have information to share with us, please
contact Joshua Rubin or Kelly Keenan by telephone at (888) 593-4771
or by email at stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website,
http://www.weisslawllp.com/contact/report_fraud/.
Attorney Advertising. Past results do not guarantee a
similar outcome.
WeissLaw LLP
Joshua Rubin
Kelly Keenan
1500 Broadway, 16th Floor
New York, NY 10036
T: 212.682.3025
F: 212.682.3010
www.weisslawllp.com
stockinfo@weisslawllp.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/weisslaw-llp-the-hyperion-therapeutics-inc-acquisition-by-horizon-pharma-plc-is-the-subject-of-a-legal-investigation-300060866.html
SOURCE WeissLaw LLP